Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer

Inclusion Criteria:

-Patients must meet all of the following inclusion criteria:

* Pathologic confirmation of stage III or IV NSCLC.
* Docetaxel therapy for cancer is clinically indicated.
* KPS\>=60% \*ANC\<1,000/mcl and Platelets\<100/mcl

Exclusion Criteria:

-Patients must meet none of the following exclusion criteria:

* WBC\< 4,000/µl, hemoglobin \< 10 g/dl, platelet count \< 100,000/µl, total bilirubin \> ULN, AST \>1.5 x ULN, alkaline phosphatase \> 2.5 x ULN, creatinine \> 1.5 mg/dl or creatinine clearance \< 50 ml/min/1.7 m2), (ANC \> 10,000/µl)
* Prior docetaxel
* Patient must have recovered from all previous treatment-related toxicity
* Concurrent use of any botanicals for anticancer intent
* Use of Jin Fu Kang or any of its constituent botanicals in the previous three weeks.
* History of allergy to any of the constituent botanicals in Jin Fu Kang.
* Pregnant or lactating women or women of childbearing potential not using effective contraception. A negative pregnancy test must be documented during the screening period for women of childbearing potential.
* Concurrent active cancer.
* Concurrent use of immunosuppressives: as an immunostimulant, astragalus-containing products are contraindicated for patients on immunosuppressive therapy.